Literature DB >> 27448695

Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.

Shuai Huang1, Yuanqing Guo, Angela Jacobi, Ziqing Li, Sheng Huang, Jianan He, Xingmo Liu, Yubo Tang.   

Abstract

BACKGROUND/AIMS: Hypoxia leads to the development of neovascularization in solid tumor by regulating VEGF expression. Aromatic hydrocarbon receptor (AHR), a receptor for dioxin-like compounds, functions as a transcription factor through dimerization with hypoxia-inducible factors 1β (HIF-1β) and inhibits the secretion of vascular endothelial growth factor (VEGF). The purpose of this study was to explore whether AHR can suppress hypoxia-induced VEGF production in prostate bone metastasis cells and repress neovascularization in endothelial progenitor cells (EPCs), and, if so, through what mechanisms.
METHODS: PC-3 or LNCaP cells induced angiogenesis was detected by Matrigel-based tube formation assay, mRNA expression levels was measured by qRT-PCR, VEGF secretion level was determined by ELISA assay, respectively.
RESULTS: AHR activation inhibits hypoxia-induced adhesiveness and vasculogenesis of EPCs induced by PC-3 or LNCaP cells under hypoxia. Moreover, AHR activation suppressed hypoxia-induced VEGF production in PC-3 and LNCaP cells (48 ± 14% in PC-3, p = 0.000; 41 ± 14% in LNCaP, p = 0.000) by attenuating HIF-1α and HIF-1β level that in turn diminished the angiogenic ability of EPCs in vitro. Furthermore, we found the mRNA level of hypoxia-inducible factors 1α (HIF-1α) (1.54 ± 0.13 fold in PC-3, p = 0.002, 1.62 ± 0.12 fold in LNCaP, p = 0.001) and HIF-1β (1.67 ± 0.23 fold in PC-3, p = 0.007; 1.75 ± 0.26 fold in LNCaP, p=0.008) were upregulated in prostate cancer bone metastasis PC-3 and LNCaP cell lines in response to hypoxia, and revealed that the regulation of VEGF by HIF-1α and HIF-1β was possibly mediated by the activation of phosphatidylinositol 3-kinase pathway.
CONCLUSION: By providing a mechanistic insight into the modulation of neovascularization by AHR ligand, we suggest that AHR ligand has a strong potential of being a new therapeutic agent with applications in the field of bone metastatic prostate cancer.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27448695     DOI: 10.1159/000445662

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  4 in total

1.  Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor.

Authors:  Mayur Choudhary; Stephen Safe; Goldis Malek
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-02-23       Impact factor: 5.187

2.  The PAX8 cistrome in epithelial ovarian cancer.

Authors:  Emily K Adler; Rosario I Corona; Janet M Lee; Norma Rodriguez-Malave; Paulette Mhawech-Fauceglia; Heidi Sowter; Dennis J Hazelett; Kate Lawrenson; Simon A Gayther
Journal:  Oncotarget       Date:  2017-11-27

Review 3.  Aryl Hydrocarbon Receptor: A New Player of Pathogenesis and Therapy in Cardiovascular Diseases.

Authors:  Tao Yi; Jinxia Wang; Kaixi Zhu; Yaoliang Tang; Shian Huang; Xiaorong Shui; Yuanlin Ding; Can Chen; Wei Lei
Journal:  Biomed Res Int       Date:  2018-06-10       Impact factor: 3.411

4.  Decreased WWOX expression promotes angiogenesis in osteosarcoma.

Authors:  Jia Wen; Zongchao Xu; Jiazhen Li; Yingqiang Zhang; Wenzhe Fan; Yu Wang; Mingjian Lu; Jiaping Li
Journal:  Oncotarget       Date:  2017-04-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.